(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

More documents

Recommendations

Info

[ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate Therapy GEP NET Conclusions • PRRT is a fascinating new tool, at least for patients with inoperable disease • High tumor response rate • Limited side-effects (only 1 % SAE) • Improvement in quality of life • Long progression free period • Compared to historical controls: survival benefit 3.5-6 yrs • New strategies are underway Cure
Future Developments for PRRT in GEPNET “towards CURE” • Treatment in earlier stage ! • Higher cumulative dose (> 800 mCi) • PRRT in combination with Chemosensitization; angiogenesis inhibitors; etc • Combination of radionuclides • Increasing the receptor density in tumors (e.g. epigenetic modulation) and/or • Decreasing the radiation effects on normal tissues: enlarging the therapeutic window • Better somatostatin analogs , antagonists
Page 1 and 2: Molecular Medicine Same Molecule/Ta
Page 3: Targeted Radionuclide Therapy with
Page 7 and 8: Molecular Medicine of GEPNET Introd
Page 9 and 10: Cytoreductive therapies for inopera
Page 11 and 12: Structure of a Radiopeptide Recepto
Page 13 and 14: Molecular Imaging at ErasmusMC
Page 15 and 16: Molecular Medicine at ErasmusMC
Page 17 and 18: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 27 and 28: PRRT with LuTate in GEPNET shows an
Page 29: [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate
Page 33 and 34: Radiolabelled [DOTA 0 ,Tyr 3 ]Octre
Page 35 and 36: Proof of Concept in Prostate Cancer

(PRRT) of Gastro-Entero-Pancreatic NeuroEndocrine Tumors

Create successful ePaper yourself

Delete template?

Save as template?